Phase II Trial of a DNA Vaccine Encoding Prostatic Acid Phosphatase (pTVG-HP [MVI-816]) in Patients With Progressive, Nonmetastatic, Castration-Sensitive Prostate Cancer

PURPOSE: We previously reported the safety and immunologic effects of a DNA vaccine (pTVG-HP [MVI-816]) encoding prostatic acid phosphatase (PAP) in patients with recurrent, nonmetastatic prostate cancer. The current trial evaluated the effects of this vaccine on metastatic progression. PATIENTS AND...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: McNeel, Douglas G., Eickhoff, Jens C., Johnson, Laura E., Roth, Alison R., Perk, Timothy G., Fong, Lawrence, Antonarakis, Emmanuel S., Wargowski, Ellen, Jeraj, Robert, Liu, Glenn
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2019
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7194451/
https://ncbi.nlm.nih.gov/pubmed/31644357
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.19.01701
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados